Project description
Targeted, locally acting drug for peripheral arterial occlusive disease
Peripheral arterial occlusive disease (PAOD) is a serious chronic cardiovascular condition associated with high cardiovascular mortality, morbidity, and amputation rates. PAOD is caused by atherosclerosis, which together with inflammation and thrombosis (blood clot formation) leads to impaired and eventually full occlusion of blood flow to the lower limbs. Funded by the European Innovation Council, the APAC-ON project is introducing a novel drug that uniquely targets these atherosclerotic sites, provides a local, long-term antithrombotic and anti-inflammatory effect, and inhibits further atherosclerosis. APAC-ON will evaluate the safety and efficacy of the drug in patients with advanced PAOD.
Objective
There is a major unmet need for effective and safe therapies for advanced peripheral arterial occlusive disease (PAOD) due to the high cardiovascular mortality, morbidity, and amputation rates in these patients. Aplagon is developing the first vascular injury -targeting product (APAC) for the local treatment of advanced PAOD. PAOD is caused by fatty deposits in lower limb arteries (atherosclerosis) that become inflamed (thromboinflammation), resulting in blood coagulation (atherothrombosis). APAC uniquely targets these vessels, prevents further atherosclerosis and downregulates thromboinflammation, the main drivers of PAOD. Aplagon has completed preclinical proof-of-concept and toxicology studies and received a regulatory approval to enter clinical studies. Aplagon has an experienced, international team, and is supported by a renowned scientific advisory board. We are applying for EIC-funding to show the safety and efficacy of APAC in PAOD/CLI-patients, a major value inflection point.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug safety
- social sciencessociologydemographymortality
- medical and health sciencesclinical medicinecardiologycardiovascular diseasesarteriosclerosis
- medical and health sciencesbasic medicinetoxicology
You need to log in or register to use this function
Keywords
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinator
00290 Helsinki
Finland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.